14.12.2022 – 20:35

Discovery Life Sciences

Huntsville, Alabama (ots/PRNewswire)

The company creates a single source for large-scale population studies, biobank characterization and multiorganic biomarker analysis to support drug and diagnostic development

Discovery Life Sciences™ (Discovery) today announced the launch of its new Proteomic Services Division and is now accepting samples from pharmaceutical and biotech companies, government agencies, non-profit and academic research centers. This innovative offering includes both exploratory and targeted proteomics using the Seer Proteograph™ Product Suite, SCIEX LC-MS/MS Systems, Olink® Proximity Extension Assay (PEA) and Luminex xMAP® platforms.

Discovery’s proteomics services labs are now integrated with the market-leading short and long-read genomics services labs and extensive global commercial biorepository of Hyper-Annotated® biosamples.

“We are very excited to open our doors to researchers and scientists around the world and provide them with access to Discovery’s scaled-up, multi-automated services to advance their biomarker discovery, clinical development and large-scale research programs,” said Michael Pisano , Executive Vice President of Proteomics at Discovery, “Our proteomics experts have carefully designed and optimized a comprehensive, platform-independent suite of state-of-the-art proteomics and proteo-genomics technologies to support any biomarker strategy, large-scale population study, and biobank characterization project. “

As part of its strategy to expand its biomarker services, Discovery signed a multi-year agreement with in January Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a breakthrough new platform for proteomics, and SCIEX, a global leader in analytical technologies for the life sciences, to form a unique Proteogenomics Consortium (PGC) for large-scale plasma proteomics studies. The PGC combines the proprietary technologies and expertise of all three companies to provide unbiased, high-resolution proteogenomic services that help discover novel biomarkers that can be mapped to underlying genetic variations.

“The Proteogenomics Consortium strategically combines these advanced plasma proteomics technologies with our world-leading expertise in short- and long-read genomics to more easily translate deep, unbiased proteomics data into discovery, translation, and clinical studies, as well as into large-scale population research programs,” said Glenn Bilawsky, CEO of Discovery. “In addition, the PGC also enables the development of new diagnostic tools for cancer, neurodegenerative, inflammatory, infectious diseases and other therapeutic areas.”

Then, in September, Discovery announced it was the largest certified commercial service provider for the Olink® PEA platform in the Americas. Olink’s PEA is a unique immuno-PCR technology that solves the dynamic range problem that has hampered plasma proteomics for decades. It enables large-scale detection and quantification of low abundance proteins in plasma. Discovery will also implement complementary multiplexed immunoassay platforms, including Luminex’s xMAP® technology, which enables customizable protein- and nucleic acid-based multiplexed assays.

Discovery offers a wide range of services including genomics, proteomics, pathology and cell biology. In addition to its extensive portfolio of services, Discovery has the world’s largest commercial biorepository and offers its partners a unified chain of custody to accelerate clinical research and development. Discovery’s integrated, multi-automated workflow enables our customers to gain deeper insights while preserving valuable samples.

About Discovery Life Sciences

Discovery Life Sciences is the biospecimens, biomarkers and proteogenomics specialists company that combines the world’s largest commercial biospecimen inventory and sourcing network with world-class multi-active biomarker service laboratories, including genomic, tissue-based biomarker, proteomic and cell-based services, to accelerate novel therapies pioneered by Biomarker and companion diagnostic programs for cancer, infectious diseases and other rare and complex diseases.

Through AllCells®, our cell and gene therapy business, we have the largest on-demand donor pool providing fresh and cryopreserved clinical-grade Research Use Only (RUO) human cell stock to support cell and gene therapy programs at every stage of development and in to support any scale.

Driven by leading scientific expertise and innovative use of modern technologies, the Discovery team works with clients to quickly overcome obstacles and get results to make critical R&D decisions at market-leading speeds. We are Science at your Service™! Visit for more information.

About Olink

Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics in collaboration with the scientific community across multiple disease areas to enable new discoveries and improve patients’ lives. Olink provides a platform of products and services used by major pharmaceutical companies and leading clinical and academic institutions to advance real-time understanding of human biology and advance 21st-century healthcare through actionable and impactful science. The company was founded in 2016 and is well established in Europe, North America and Asia. Olink’s headquarters are in Uppsala, Sweden.


SCIEX delivers solutions for the precise detection and quantification of molecules that enable our customers to protect and promote the well-being and safety of all people. We have been at the forefront of mass spectrometry for 50 years. Since introducing the first commercially successful triple quadrupole in 1981, we have developed breakthrough technologies and solutions that impact life-changing research and outcomes.

Today we continue to pioneer reliable solutions in mass spectrometry and capillary electrophoresis. Our customers are able to respond quickly to environmental threats, better understand disease biomarkers, improve patient care in the clinic, bring relevant medicines to market faster, and make food healthier and safer.

That’s why thousands of life scientists around the world choose SCIEX to get the answers they can count on to make important decisions that positively impact life.

For more information please visit

Information about Seer

Seer™ is a life sciences company developing transformative products that open new doors to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary nanoparticles, consumables, automation tools, and software to perform pristine, deep, and rapid large-scale proteome analysis in hours. Seer designed the Proteograph workflow to be efficient and easy to use. It leverages widely used laboratory instruments to provide a decentralized solution that can be adopted by almost any laboratory. Seer’s Proteograph Product Suite is intended for research use only and not for diagnostic procedures. For more information please visit

Logo –

View original content:

Press contact:

Brian Bennett,;

Original content by: Discovery Life Sciences, transmitted by news aktuell

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.